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Dear Editor,
We are grateful to Gurevich and colleagues for their correspondence
[1], highlighting our review of clinical outcomes in male patients with
Fabry disease after enzyme replacement therapy (ERT) [2]. This is one
of a series of papers published in Molecular Genetics and Metabolism
(MGM) or MGM Reports that describe the results of a unique systematic
review of the published literature on therapeutic outcomes in patients
with Fabry disease, initiated and guided by established experts in this
field with extensive experience in patients' clinical care [2–6].
We commend the authors for highlighting the importance of stan-
dardisation in the design, conduct and reporting of systematic reviews
and concur with their comments on the necessity to report on bias in
the published literature. The initial series, as submitted to MGM, in-
cluded a manuscript with the detailed description of the methodology
and bias evaluation for all papers. However, MGM's peer review as
stand-alone publication resulted in conflicting feedback from reviewers,
and this paper has now been published by the European Journal of
Medical Genetics [7].
We confirm that the data search and extraction for this series was
conducted in line with recommended practice and that our analysis
included a grading of evidence using the levels of evidence classifica-
tion published by the Oxford Centre for Evidence-Based Medicine [8].
All Grade 1–3 publications were assessed for risk of bias based on the
Cochrane tool for assessing bias originally developed for randomised
trials [9]. Importantly, pharmaceutical sponsorship of a study was also
noted and when insufficient data were available to make a judgement
on its impact, the item was noted as a potential risk.
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